NewsRoom Articles - Page 94 of 154 - PsychedelicNewsWire (PNW)

TuesdayJun 15, 2021 2:45 pm

Why NIH Should Get Involved in Psychedelics Research

Investing in medicinal psychedelic research in the recent past was considered risky. Now, however, financiers and entrepreneurs are injecting money into the development of psychedelic therapies for behavioral and mental health issues. Despite this, one of the biggest public financiers of medical research in the world — the National Institutes of Health — is yet to do so. The organization’s absence in psychedelic medicine may potentially be slowing the development of new innovative treatments as well as preventing researchers from entering the field. Records show that various human populations have used psychedelics such as psilocybin, mescaline, MDMA, LSD, ibogaine, DMT…

TuesdayJun 15, 2021 1:17 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Commences Sale of Rapid COVID-19 RT-PCR Test Kits in Germany Amid Potential Surge in Demand

XPhyto’s distribution, storage, and logistics partner, Max Pharma GmbH, began the sale and delivery of its rapid test kits (Covid-ID Labs) in Germany on May 25 Max Pharma will sell Covid-ID Labs at volume-dependent pricing comparable to other COVID-19 PCR test products on the market The announcement comes as Germany reopens, meaning XPhyto is likely to benefit from a raft of regulatory requirements instituted by the government, which could potentially increase demand The Covid-ID Labs is both fast and accurate, factors that could make it the go-to product, given the inaccuracies and low sensitivity of many rapid antigen tests As…

TuesdayJun 15, 2021 9:00 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Expands Sales into Public Sector with BC Liquor Distribution Board Purchase

PULL secures edible cannabis gummies order from British Columbia Liquor Distribution Branch PULL’s cannabis gummies produced in blister packs using proprietary manufacturing system licensed from US-based Taste-T, LLC SKUs include 10 mg THC options in Fire Burst, Strawberry, and Mango flavors, three additional non-THC SKUs currently in development Global CBD gummies market estimated at $1.6 billion in 2020, 30.7% CAGR from 2021 to 2028 Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, recently secured an initial purchase order through subsidiary Pure Extracts Manufacturing Corp., from…

MondayJun 14, 2021 2:32 pm

Join us for World Psychedelics Day – June 20th (6·20)

World Psychedelics Day (WPD) is an annual event dedicated to building awareness of, and respect for, the therapeutic and life-enhancing potential of psychedelics. Taking place Sunday, June 20th, 6·20, WPD honours the breakthroughs in scientific research and Indigenous psychoactive plant medicines which gave rise to the “Psychedelic Renaissance”. “World Psychedelics Day offers people the opportunity to seek out truthful information about psychedelics, to discover those who are knowledgeable, qualified by deep research, or their own experience, who can share useful insights,” says Dr. Andrew Weil, Director of the Andrew Weil University of Arizona Center for Integrative Medicine and Spokesperson for…

MondayJun 14, 2021 2:30 pm

More Men Seeking Psychedelic-Assisted Therapy for Mental Health Conditions

Mental health awareness has become popular in the recent past, with more individuals being open about discussing their struggles with mental health while more organizations and people also advocate for proper steps and assistance to be provided to those in need. Given that June is Men’s Mental Health month, it’s only fitting that we promote overall wellness while raising awareness about issues and health care trends that impact men. More men have been discussing mental health more openly, which helps shatter cultural stigmas. This trend is a break from past patterns as traditionally, mental health has not been a typical…

MondayJun 14, 2021 9:51 am

The MDMA Conference

Virtual Event Date: Tues. June 15, 2021 Time: 9:00 AM EST The MDMA Conference is a virtual conference exploring the potential of the psychoactive drug MDMA, at the intersection of drug development & safety, clinical care and applications, law & regulation, business & markets, science & research, history & culture. The MDMA Conference will consist of six keynote talks, on topics such as ‘MDMA-assisted psychotherapy for treating alcohol use disorder’, ‘The Culture of MDMA: The Go-To Medicine in America’s Future’, and ‘MDMA & Clinical Applications’ among various others. Featuring a range of thought and corporate leaders from across the MDMA…

FridayJun 11, 2021 1:00 pm

Scientific Evidence Mounts on Therapeutic Value of Psychedelics

Scientific evidence regarding the use of psychedelic substances as therapies for various mental conditions has been growing recently, with various studies on these substances being conducted. For instance, the Johns Hopkins Center for Psychedelic and Consciousness Research, which is the biggest psychedelic research center globally, has been carrying out studies on substances such as psilocybin, MDMA and ketamine to evaluate whether they can be used as treatments for Alzheimer’s, post-traumatic stress disorder and depression. Additionally, the University of Toronto is planning on conducting research on the use of psilocybin, which is the active ingredient found in magic mushrooms; the university…

FridayJun 11, 2021 9:00 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Sponsor Kernel Flow, Ketamine Feasibility Study

Feasibility study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics Cybin, Kernel working together to leverage proprietary Kernel Flow device for psychedelic-based studies and clinical trials Ketamine is a dissociative injected anesthetic that blocks sensory perception Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced a key step forward in its focus on progressing psychedelic therapeutics. The company will be sponsoring a feasibility study of the Kernel Flow technology; the study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/BW1Jn). “We still have much to learn about what is occurring in the brain during a psychedelic…

ThursdayJun 10, 2021 10:45 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright’s Upcoming Virtual Psychedelics Conference

Tryp Therapeutics’ Chairman and CEO Greg McKee will present at the virtual Psychedelics in Psychiatry and Beyond Conference planned for Thursday, June 17, 2021 As part of his presentation, McKee will discuss Tryp’s business and its pipeline, which includes its proprietary psilocybin-centered drug development program Tryp will present alongside other pharmaceutical companies leading research in psychedelic-assisted therapeutics Psychedelics have increasingly drawn the attention of different players and companies thanks to the research-driven revelations regarding their utility in treating a wide range of neuropsychiatric diseases. As a pharmaceutical company that has been furthering such research – specifically on psilocybin, a psychedelic…

ThursdayJun 10, 2021 10:30 am

Therapeutic Psychedelics Could Be Worth at Least $6.5 Billion by 2030

A recently released report forecasts that by 2030, the psychedelics therapeutics market may be worth more than $6 billion. The annualized rate of growth is predicted to be almost 15%. A lot of research on psychedelics has been conducted in the recent past, with a growing body of evidence suggesting that administering psychedelic substances such as LSD and psilocybin, combined with psychotherapy, may help manage the symptoms of various mental health conditions (i.e., substance use disorders and depression). To date, almost 150 types of psychedelic substances that may be used as therapeutics have been identified. These psychedelics have shown that…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000